Biohaven Ltd. amended its Equity Distribution Agreement to increase the aggregate offering price for its at-the-market equity program to $682 million, with up to $350 million available for sale from May 4, 2026.
Key takeaways
Amendment No. 2 increases the aggregate offering price under the Equity Distribution Agreement from $150 million to $682 million.
Up to $350 million of common shares may be sold through J.P. Morgan Securities LLC from May 4, 2026.
Sales will be conducted via an 'at-the-market' equity offering program on the New York Stock Exchange.
The offering is pursuant to an effective shelf registration statement (File No. 333-295531) filed on May 4, 2026.
The amendment updates legal counsel references from Locke Lord LLP to Troutman Pepper Locke LLP.